Lonza sets new mid-term targets, confirms 2026 outlook

Swiss contract drug manufacturer Lonza set new mid-term ​targets and confirmed its 2026 outlook on Wednesday ahead of its capital markets day, while saying third-quarter ‌performance was in line with expectations across its business areas.

Galderma to buy US firm ZO Skin Health for $1.5 billion

Swiss skincare firm Galderma has agreed to acquire US ​company ZO Skin Health for an enterprise value of $1.5 billion, it said on Wednesday, confirming a ‌report published by Reuters earlier in the day.

Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion

Danish obesity-drug developer Zealand Pharma has partnered with US biotechnology company Generate ​Biomedicines to develop protein-based treatments for obesity and other metabolic diseases using AI, in a deal worth up to $1.2 ‌billion.

Bumble swipes right on $1.3 billion go-private deal amid online dating industry reset

Bumble said on Tuesday it had agreed to be taken private by Ithaca Holdings in a ​deal valued at $1.3 billion, as the dating app pushes forward with its months-long turnaround amid shifting Gen Z dating habits and declining paying users.

Nvidia buys stakes in French tech startups Doctolib, Genesis AI

US chipmaker Nvidia ​has agreed to buy stakes in French technology startups ‌Doctolib and Genesis AI, the two French ⁠companies said ​on Tuesday.

BioNTech's mRNA cancer therapy misses first goal in head and neck trial

BioNTech said on Tuesday its experimental mRNA cancer immunotherapy ​failed to meet the first main goal of a mid-to-late-stage trial in patients with head ‌and neck cancer.

Agilent to buy pathology software maker Proscia for $240 million

Agilent Technologies said on Tuesday it ​would acquire pathology software maker Proscia for $240 million in cash, plus ‌up to $30 million tied to future performance targets, ⁠as the laboratory ​equipment maker expands ⁠its push into AI-enabled diagnostics.

Pope Leo leaves Vatican for hospital ahead of surgery on lung nodule

Pope Leo left ​the Vatican on Tuesday in a convoy of vehicles ‌ahead of his expected admission to Rome's ⁠Gemelli hospital ​for surgery to ⁠remove a small growth ‌found on one ‌of his lungs, the first ⁠major health ⁠issue of his 17-month tenure.

Roche strikes obesity drug licensing deal worth up to $1.16 billion with Chinese Rona Therapeutics

Swiss drugmaker Roche entered ​a licensing agreement worth up to $1.16 billion with Rona ‌Therapeutics for its investigational obesity drug candidate, ⁠the Chinese ​biotech firm said ⁠on Tuesday.